Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Renal Insufficiency 1Kidney Failure, Chronic 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Kidney Transplantation × Clear all
NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡